OncoMatch/Clinical Trials/NCT06150157
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Is NCT06150157 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including JNJ-88549968 and Ruxolitinib for neoplasms.
Treatment: JNJ-88549968 · Ruxolitinib · Momelotinib — The purpose of this study is to characterize safety and to determine the Recommended Phase 2 Dose (RP2D\[s\]) and optimal dosing schedule(s) of JNJ-88549968 in part 1 (Dose Escalation); to characterize the safety of JNJ- 88549968 at RP2D(s) in part 2 (Cohort Expansion). For U.S. sites: the purpose of this study is to characterize the safety and to determine the RP2D(s) and optimal dosing schedule(s) of JNJ-88549968 in Part 1 and part 1b (Dose Escalation), and to characterize the safety of JNJ-88549968 at the RP2D(s) in Part 2 and part 2b (Cohort Expansion), when given as monotherapy in essential thrombocythemia (ET) or myelofibrosis (MF), and with ruxolitinib or momelotinib in MF only.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Other
Biomarker criteria
Required: CALR driver mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: allogenic stem cell transplant
Exception: allowed if >6 months before first dose and no evidence of GVHD requiring immunosuppressant therapy
Prior treatment with allogenic stem cell transplant less than or equal to (<=) 6 months before the first dose of JNJ-88549968 or evidence of graft versus host disease (GVHD) that requires immunosuppressant therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope · Duarte, California
- UCHealth Cancer Care Anschutz Medical Campus University of Colorado Cancer Center · Aurora, Colorado
- Moffit Cancer center · Tampa, Florida
- University of Michigan · Ann Arbor, Michigan
- Memorial Sloan Kettering Cancer Center · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06150157 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior allogenic stem cell transplant disqualifies patients from enrollment.
Does this trial require CALR?
Yes, CALR driver mutation is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify